Assessing BIM expression as a cause and marker for resistance to targeted therapi
评估 BIM 表达作为靶向治疗耐药性的原因和标志
基本信息
- 批准号:8916050
- 负责人:
- 金额:$ 19.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectApoptosisApoptoticBCL2 geneBCL2L11 geneCancer CenterCancer ModelCancer PatientCell DeathCell LineChromatinClinicalCountryDNA Sequence AlterationDataDiseaseDown-RegulationERBB2 geneEpidermal Growth Factor ReceptorEpigenetic ProcessEquilibriumFamily memberGeneral HospitalsGenerationsGenotypeGoalsGrowthHealthIn VitroIn complete remissionLaboratoriesLearningMalignant NeoplasmsMalignant neoplasm of lungMassachusettsMethodsModelingMutationOncogenesOutcomePatientsPharmaceutical PreparationsPharmacologic SubstancePhosphotransferasesPopulationProgressive DiseaseRegimenRelative (related person)ResistanceResistance developmentSignal TransductionTechnologyTestingTherapeuticTranslational ResearchTreatment outcomealternative treatmentbasecancer cellfallsgenetic analysisimprovedin vivomalignant breast neoplasmmimeticsmutantoncogene addictionpatient populationpro-apoptotic proteinresearch studyresistance mechanismresponsetargeted cancer therapytargeted treatmenttherapy resistanttreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Over, the past several years, we have learned that subsets of genetically defined cancers require an activated kinase for their growth and survival. In these cancers, the kinase is often directly activated by genetic alteration; mutation, amplification or translocation. These cancer cells are "addicted" to the genetically activated kinase, and they die, via apoptosis, upon inhibition of the kinase. This is known as "targeted therapy." These findings have already had a transformative impact on cancer therapeutics. In 2009, Massachusetts General Hospital (MGH) created a Translational Research Laboratory to perform multiplexed genetic analyses on the lung cancers of all patients being treated at MGH, and we have genotyped over 600 cases in the past year. This technology is quickly being implemented at many other cancer centers throughout the country, highlighting the importance of this burgeoning field. Intriguingly, while many of these genetically defined cancers (such as EGFR mutant and ALK translocated) have dramatic responses following targeted therapies, some have either poor responses or no responses, for largely unknown reasons. While resistance in some of these cancers are thought to be caused by secondary mutations that result in sustained intracellular signaling in the presence of targeted therapy, a large population
of patients, whom do not carry these mutations in their cancers, are resistant for unknown reasons. We have found that targeted therapies are most effective when they induce both growth arrest and cell death (apoptosis). When they fail to, responses are mitigated. The inadequacy of targeted therapies to induce apoptosis may be caused by a deficiency in the pro-apoptotic protein, BIM. In this application, we propose that, in the setting of oncogene addiction,
resistance arises when targeted therapies fail to induce apoptosis in oncogene-addicted cancers, despite downregulation of the intracellular signaling and posit that these cancers fail to
undergo apoptosis because of deficiencies in the expression of BIM. We highlight preliminary data that supports these hypotheses, including functional in vitro and in vivo analyses, predictive
power of BIM expression to apoptosis in cell line models, and patient data suggesting BIM expression can prospectively predict patient response to EGFR mutant targeted therapies. Lastly, we discuss potential, testable pharmaceutical strategies to overcome BIM deficiency in these cancers. If our testable hypothesis is proven correct, determining BIM expression in pre-treatment levels of oncogene- addicted cancers will change the way this growing population of cancer patients is treated.
描述(由申请人提供):在过去的几年中,我们已经了解到,基因定义的癌症的子集需要活化的激酶来促进其生长和存活。在这些癌症中,激酶通常通过遗传改变、突变、扩增或易位直接激活。这些癌细胞对遗传活化的激酶“上瘾”,并且在激酶被抑制后,它们通过细胞凋亡而死亡。这就是所谓的“靶向治疗。“这些发现已经对癌症治疗产生了变革性的影响。2009年,马萨诸塞州总医院(MGH)创建了一个转化研究实验室,对在MGH接受治疗的所有肺癌患者进行多重基因分析,我们在过去一年中对600多例病例进行了基因分型。这项技术正在全国许多其他癌症中心迅速实施,凸显了这一新兴领域的重要性。有趣的是,虽然许多这些基因定义的癌症(如EGFR突变体和ALK易位)在靶向治疗后有显著的反应,但有些癌症的反应很差或没有反应,原因很大程度上未知。虽然这些癌症中的一些的抗性被认为是由在靶向治疗存在下导致持续的细胞内信号传导的继发性突变引起的,但是大的群体中的许多人都认为,
的患者,他们的癌症中没有携带这些突变,但由于未知的原因而产生耐药性。我们已经发现,靶向治疗是最有效的,当他们诱导生长停滞和细胞死亡(凋亡)。如果他们不这样做,反应就会减轻。诱导细胞凋亡的靶向治疗的不足可能是由促凋亡蛋白BIM的缺乏引起的。在本申请中,我们提出,在癌基因成瘾的情况下,
当靶向治疗不能诱导癌基因成瘾性癌症的细胞凋亡时,尽管细胞内信号转导下调,
由于BIM表达的缺陷而发生凋亡。我们强调支持这些假设的初步数据,包括体外和体内功能分析,预测
BIM表达对细胞系模型中细胞凋亡的影响,以及提示BIM表达可前瞻性预测患者对EGFR突变体靶向治疗的反应的患者数据。最后,我们讨论了潜在的,可测试的药物策略,以克服这些癌症中的BIM缺陷。如果我们的可测试假设被证明是正确的,那么确定癌基因成瘾癌症治疗前水平的BIM表达将改变不断增长的癌症患者群体的治疗方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anthony Charles Faber其他文献
Anthony Charles Faber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anthony Charles Faber', 18)}}的其他基金
MYCN drives a ferroptotic vulnerability in neuroblastoma
MYCN 导致神经母细胞瘤铁死亡的脆弱性
- 批准号:
10736479 - 财政年份:2023
- 资助金额:
$ 19.11万 - 项目类别:
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma
SUMO化破坏对 SS18-SSX 驱动的滑膜肉瘤具有毒性
- 批准号:
10736999 - 财政年份:2023
- 资助金额:
$ 19.11万 - 项目类别:
Neuroblastoma reliance on DNMT1 through amplified MYCN
神经母细胞瘤通过扩增 MYCN 依赖 DNMT1
- 批准号:
10410501 - 财政年份:2020
- 资助金额:
$ 19.11万 - 项目类别:
Neuroblastoma reliance on DNMT1 through amplified MYCN
神经母细胞瘤通过扩增 MYCN 依赖 DNMT1
- 批准号:
10159228 - 财政年份:2020
- 资助金额:
$ 19.11万 - 项目类别:
ABT-199 based therapies to treat neuroblastoma
基于 ABT-199 的神经母细胞瘤疗法
- 批准号:
9899951 - 财政年份:2017
- 资助金额:
$ 19.11万 - 项目类别:
ABT-199 based therapies to treat neuroblastoma
基于 ABT-199 的神经母细胞瘤疗法
- 批准号:
9289519 - 财政年份:2017
- 资助金额:
$ 19.11万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 19.11万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 19.11万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 19.11万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 19.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists